Else Nutrition (TSXV:BABY) (OTCPK:BABYF): RichTV Live Interview

Else Nutrition

Else Nutrition Holdings Inc. (TSXV:BABY) (OTCPK:BABYF) is a food and nutrition company that primarily targets the infant, toddler, and children markets. Last week, Rich brought the company to the attention of his community members. Since then, BABY stock has rocketed up nearly 50% from $0.31 to $0.46.

Today, Rich talks to Else’s Director of Digital Marketing, Barak Orenstein. Orenstein has more than 15 years of consumer goods marketing and was formerly a brand director at Sodastream, L’Oreal, and Danone.

“We’re in the process of building our brand in advance of the launch of our first toddler nutritional drink in Q2 of 2020,” says Orenstein.

Else Nutrition’s 100% Plant-Based Formula

Orenstein explains that the infant nutrition industry has been around for 120 years, and throughout that time, it’s been dominated by two product sources: cow-based protein and soy-based protein. Both are known allergens, leaving many children unable to consume those products.

“We’re bringing to market the first all-natural 100% plant-based infant nutritional formula,” he says. “So at Else we like to say, ‘we’re not just a formula, we’re a solution.’ And we’re providing a real solution and innovation in a market that’s been stagnant.”

Enter Your E-mail Address To Subscribe

* indicates required
 

Else Nutrition’s formula is derived from almonds and buckwheat. It is entirely free of pesticides, hormones, antibiotics, gluten, and phytoestrogens. So not only is it perfect for children with allergies, it’s also the right formula for parents who want to ensure their children are getting the nutrition they need.

Studies show that approximately 1 in 12 families are raising their children vegan. In addition, approximately 31% of Americans consider themselves flexitarians, meaning they are generally open to plant-based diets, though will still eat meat on occasion.

This positions Else Nutrition as the Beyond Meat of infant nutrition. Orenstein says his company has received that compliment a lot.

“We’re humbled by that, but we’re really focused on our vision of providing a foundation for infant nutrition for generations to come,” he says.

Market, IP Protection, and Future Plans

The global market value for infant formula is projected to be $90 billion USD by 2025, with a CAGR of 9.35%. One of the primary reasons this market is growing so fast is that there is an increasing demand for milk formulas with additional nutrition.

Fortunately, Else Nutrition enjoys very strong IP protection, so it can properly capitalize on being the first mover in the plant-based infant formula space. Its formula has been granted patents in 20 countries, including the United States, Australia, Japan, Ukraine, Russia, South Africa, and New Zealand. The company also has a further 50+ patents pending.

In addition, Else is already earning revenue in Israel from the sale of its vegan baby snacks and other accessories. These products generated $900,000 for the company last year.

“Currently we’re focused on commercializing and launching our first product to [the US] market, which will be liquid- and powder-based toddler nutritional drinks. Those are slated to launch in the spring of 2020,” explains Orenstein. “We’ll be following that up with 0-12 month infant nutrition formula.”

Else Nutrition may be a departure from Rich’s traditional stock coverage, but when he sees a company poised for growth, he makes sure he brings it to RichTV Live. Keep watching for more updates about this exciting business.

Let us know your thoughts by joining the conversation in the comments below.

Featured image: DepositPhotos © studioM

Please See Disclaimer

If You Liked This Article Click To Share


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Else Nutrition Holdings Inc. Bitrics Markets Group Inc. and/or Iman Consulting Group has or expects to receive $800 Canadian dollars from Market Jar Media Inc. for the creation and distribution of the video.

3) Statements and opinions expressed are the opinions of the author and not Bitrics Markets Group Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Bitrics Markets Group Inc. for this Article. Bitrics Markets Group Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Bitrics Markets Group Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Bitrics Markets Group Inc. relies upon the authors to accurately provide this information and Bitrics Markets Group Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Bitrics Markets Group Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Bitrics Markets Group Inc. does not render general or specific investment advice and the information on richtvlive.com should not be considered a recommendation to buy or sell any security. Bitrics Markets Group Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

5) Bitrics Markets Group Inc. and its owners, members, officers, directors, partners and consultants may own shares of the profiled companies, which it may sell at any time, including as soon as it deposits such shares into its trading accounts, during our campaign of the profiled companies stock, after our campaign or at any other time. We also may buy and sell securities in the profiled companies which may cause (a) decline in the price of the profiled companies stock due to our selling activities, (b) increased volatility due to our buying and selling of the profiled companies stock and (c) permit us to make substantial profits while we are profiling each of these companies, yet may result in a diminished value to the stock for investors. for any company mentioned in the Article.